SAN.PA - Sanofi

Paris - Paris Delayed price. Currency in EUR
84.54
+0.94 (+1.12%)
At close: 5:35PM CEST
Stock chart is not supported by your current browser
Previous close83.60
Open83.90
Bid71.12 x 1000
Ask71.74 x 44000
Day's range83.77 - 84.69
52-week range24.55 - 87.65
Volume1,109,215
Avg. volume20,328
Market cap104.02B
Beta0.73
PE ratio (TTM)11.79
EPS (TTM)7.17
Earnings date2 Nov 2017
Dividend & yield3.30 (3.40%)
Ex-dividend date2017-05-16
1y target est86.83
  • Market Realist7 hours ago

    Vaccines Business Expected to Boost Sanofi’s Revenues in 2017

    In 2Q17, Sanofi’s (SNY) vaccine business reported revenues of 1.0 billion euros, which is a YoY rise of 26.2% on a CER basis and 19.2% on a CER and CS basis.

  • Market Realist9 hours ago

    Sanofi’s Kevzara Could Be Solid Addition to Rheumatoid Arthritis

    Launched in US markets in June 2017, Kevzara (sarilumab), Sanofi (SNY) and Regeneron’s (REGN) IL-6 receptor antibody, has received favorable feedback from the physician community.

  • Regeneron Advances Science To Attack Arthritis, Eye Disease, More
    Investor's Business Daily10 hours ago

    Regeneron Advances Science To Attack Arthritis, Eye Disease, More

    Regeneron became a star with its treatment for a common eye disease, but treatments for dermatitis, arthritis, asthma and cancer could bring superstardom.

  • Market Realist10 hours ago

    Dupixent May Be Strong Growth Driver for Sanofi in the Future

    Regeneron (REGN) and Sanofi’s (SNY) Dupixent has seen stronger total prescription (or TRx) performance since its launch than Cosentyx, the dermatology biologic drug by Novartis (NVS).

  • The Wall Street Journal10 hours ago

    [$$] Warp Drive Bio, Roche Forge $387 Million Antibiotics Pact

    Warp Drive Bio Inc. could wind up $387 million richer thanks to a new antibiotic drug deal struck with Roche.

  • Market Realist3 days ago

    Specialty Segment Drives Sanofi’s Revenue Growth in 2017

    In 2Q17, Sanofi’s (SNY) Sanofi Genzyme, its specialty care business, reported revenues of 1.7 billion euros, which is a 13.6% rise YoY (year-over-year).

  • Market Realist3 days ago

    Sanofi and Its Peers: Analysts’ Recommendations in October

    Of the three analysts covering Sanofi in October 2017, two have rated the stock a “strong buy,” and one has rated it a “hold.”

  • Forbes3 days ago

    Big Pharma Killed The Cancer Drug He Invented. He Raised $22 Million To Revive It

    “They were asking for help to get the drug back. They were dying. Most of them died. It was very motivating to try to get it back."

  • Motley Fool4 days ago

    A New FDA Approval Sends Small Cap Flexion Soaring

    Flexion's non-opioid pain management drug has huge potential, and it's looking to expand into more indications.

  • Reuters - UK Focus4 days ago

    Sanofi boosts vaccines business with 170 mln euro investment

    VAL-DE-REUIL, France, Oct (Shenzhen: 000069.SZ - news) 12 (Reuters) - Sanofi (LSE: 0O59.L - news) on Thursday expressed confidence in the growth of its influenza vaccines after committing to invest 170 million euros to expand its manufacturing facility at Val-de-Reuil in north-western France. The new facility will allow Sanofi Pasteur, the group's vaccines arm, to expand the supply of VaxigripTetra, its newest "quadrivalent" vaccine, to up to 70 countries from around 20 currently. VaxigripTetra protects against four strains of the flu virus and competes with other quadrivalent and "trivalent" products already on the market.

  • Reuters - UK Focus5 days ago

    Sanofi invests 170 million euros in French vaccines facility

    Sanofi will invest 170 million euros to expand its vaccines manufacturing site at Val-de-Reuil in north-western France, in a drive aimed at boosting the production of one of its influenza vaccines. The ...

  • GlobeNewswire5 days ago

    Sanofi invests €170 million in new vaccine production facility in France

    Sanofi invests €170 million in new vaccine production facility in France - Expansion at Val de Reuil reinforces the company`s position as a global leader in seasonal flu vaccines - Paris, France - October ...

  • Biotech Stock Roundup: Amgen's Imlygic Data Promising, Regeneron Scores Win in PCSK9 Lawsuit
    Zacks5 days ago

    Biotech Stock Roundup: Amgen's Imlygic Data Promising, Regeneron Scores Win in PCSK9 Lawsuit

    With third quarter earnings round the corner, it was a relatively slow week with key updates including Regeneron (REGN) and partner Sanofi's win in the PCSK9 litigation.

  • This Biotech Hit Record High; Could Undercut Regeneron In Eczema
    Investor's Business Daily6 days ago

    This Biotech Hit Record High; Could Undercut Regeneron In Eczema

    AnaptysBio soared Tuesday after its eczema drug appeared to outperform a potential blockbuster rival drug from Regeneron and Sanofi.

  • Emergent BioSolutions Acquires Sanofi's Smallpox Vaccine Unit
    Zacks7 days ago

    Emergent BioSolutions Acquires Sanofi's Smallpox Vaccine Unit

    Emergent BioSolutions (EBS) announced that it has acquired FDA-licensed smallpox vaccine's business of Sanofi (SNY) ??? ACAM2000.

  • Why Regeneron's Patent Win Is Worse For Amgen Than You Think
    Investor's Business Daily10 days ago

    Why Regeneron's Patent Win Is Worse For Amgen Than You Think

    Amgen's patents covering LDL cholesterol-lowering drug Repatha are likely to be invalidated, an analyst says.

  • Regeneron and Sanofi Get Favorable Ruling Against Amgen
    Zacks10 days ago

    Regeneron and Sanofi Get Favorable Ruling Against Amgen

    Regeneron Pharmaceuticals(REGN) and partner Sanofi, Inc. (SNY) receives a favorable ruling from the Court of Appeals for the Federal Circuit relating to Praluent.

  • At least six funds interested in Sanofi European generic drugs unit - Le Figaro
    Reuters11 days ago

    At least six funds interested in Sanofi European generic drugs unit - Le Figaro

    French pharmaceutical group Sanofi (SASY.PA) is set to start the process to sell its generic drug business in Europe, and at least six funds have expressed interest to investment banks mandated by group, France's Le Figaro newspaper reported. Rothschild and JP Morgan, two investment banks mandated by Sanofi to handle the divestment, will send out memos to potential buyers in the next few weeks, Le Figaro said in its Friday edition. Sources told Reuters in March that Rothschild [ROT.UL], JP Morgan (JPM.N) and Morgan Stanley (MS.N) had been asked to organise the long-awaited deal.

  • Reuters - UK Focus11 days ago

    At least six funds interested in Sanofi European generic drugs unit -Le Figaro

    French pharmaceutical group Sanofi is set to start the process to sell its generic drug business in Europe, and at least six funds have expressed interest to investment banks mandated by group, France's ...

  • The Wall Street Journal11 days ago

    [$$] Appeals Court Rules Against Amgen in Patent Case

    A U.S. federal appeals court said Regeneron Pharmaceuticals and partner Sanofi can continue selling their cholesterol drug, dealing a blow to rival Amgen, which had accused the companies of violating its ...

  • Reuters - UK Focus12 days ago

    UK's BTG to buy Roxwood Medical for up to $80 mln

    British drugs company BTG Plc said on Thursday it will buy U.S.-based cardiovascular catheter maker Roxwood Medical for up to $80 million. The deal, which is expected to be accretive to adjusted profit ...

  • Reuters - UK Focus14 days ago

    Oxford team to test universal flu vaccine in world first

    LONDON, Oct (Shenzhen: 000069.SZ - news) 3 (Reuters) - A seasonal flu vaccine that would be the first in the world to fight all types of the virus is to be tested in a two-year clinical trial involving more than 2,000 patients by researchers in Oxford. The so-called universal vaccine was developed by Oxford University's Jenner Institute and Vaccitech, a spin-out biotech company founded by Jenner scientists. Current flu vaccines have to be changed each year to match strains of virus circulating at the time and they do not always protect people that well, especially older patients with weak immune systems.

  • Reuters - UK Focus24 days ago

    Korea tensions keep European shares in check before Germany vote

    LONDON/MILAN, Sept 22 (Reuters) - European shares steadied on Friday, as tensions over North Korea kept some investors on the sidelines ahead of a national election in Germany that conservative Chancellor Angela Merkel looks set to win. French cosmetics giant L'Oreal was a notable gainer on speculation about ownership changes, rising as much as 6.7 percent after billionaire Liliane Bettencourt, whose family founded the firm and still owns the largest stake in it, died.

  • Reuters - UK Focus25 days ago

    North Korea tension weighs on European shares but L'Oreal rallies

    European shares fell in early deals on Friday on fresh tension on the North Korean front, while L'Oreal rallied in Paris on talk about possible ownership changes at the cosmetics giant. L'Oreal rose more ...

  • Business Wire26 days ago

    Alnylam and Sanofi Report Positive Topline Results from APOLLO Phase 3 Study of Patisiran in Hereditary ATTR (hATTR) Amyloidosis Patients with Polyneuropathy

    Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, and Sanofi Genzyme, the specialty care global business unit of Sanofi, announced today that the APOLLO Phase 3 study of patisiran, an investigational RNAi therapeutic being developed for patients with hereditary ATTR amyloidosis with polyneuropathy, met its primary efficacy endpoint and all secondary endpoints. The primary endpoint for the study was the change from baseline in the modified neuropathy impairment score (mNIS+7) at 18 months.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes